In addition, this meta-analysis also investigated the risk of three CDK4/6 inhibitors plus different endocrine therapies on the occurrence of specific AEs and suggested that ribociclib and abemaciclib were associated with lower severe neutropenia but higher gastrointestinal toxicity compared with palbociclib. This evidence concerns the gene CDK4 and Decreased total neutrophil count.